Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040

Acta Ophthalmologica

Volumn 91, Issue 4, 2013, Pages 307-311

  Lindekleiv, Haakon ^a   Erke, Maja Gran ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

age related macular degeneration; epidemiology; prevalence

Indexed keywords

AGE DISTRIBUTION; AGED; AGING; ARTICLE; CONTROLLED STUDY; DANISH; DENMARK; ETHNIC GROUP; FEMALE; GEOGRAPHIC ATROPHY; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; NORWEGIAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SCANDINAVIA; SEX DIFFERENCE; SUBRETINAL NEOVASCULARIZATION; SWEDEN; SWEDISH;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; FORECASTING; HUMANS; MACULAR DEGENERATION; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SCANDINAVIA; SEX DISTRIBUTION;

EID: 84878444190     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02399.x     Document Type: Article

References (32)

1. Age-Related Eye Disease Study Research Group (2001): A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
2. Anastasopoulos E, Yu F, &, Coleman AL, (2006): Age-related macular degeneration is associated with an increased risk of hip fractures in the medicare database. Am J Ophthalmol 142: 1081-1083.
3. Arroyo J, Trobe J, &, Schmader KE, (2011): Age-related macular degeneration: treatment and prevention. In:, D. S. Basow, (Ed.) UpToDate. Retrieved from http://www.uptodate.com/.
4. Augood CA, Vingerling JR, de Jong PT, et al., (2006): Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124: 529-535.
5. Bjornsson OM, Syrdalen P, Bird AC, Peto T, &, Kinge B, (2006): The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular Study. Acta Ophthalmol Scan 84: 636-641.
6. Buch H, Vinding T, la Cour M, Appleyard M, Jensen GB, &, Nielsen NV, (2004): Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults-the Copenhagen City Eye Study. Ophthalmology 111: 53-61.
7. Chew EY, Coleman HR, Chan CC, &, Ferris FL, (2008): Age-related macular degeneration. Lancet 372: 1835-1845.
8. Chong EW, Robman LD, Simpson JA, et al., (2009): Fat consumption and its association with age-related macular degeneration. Arch Ophthalmol 127: 674-680.
9. Christen WG, Manson JE, Glynn RJ, Gaziano JM, Chew EY, Buring JE, &, Hennekens CH, (2007): Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians. Arch Ophthalmol 125: 333-339.
10. Coleman AL, Yu F, Ensrud KE, Stone KL, Cauley JA, Pedula KL, Hochberg MC, &, Mangione CM, (2010): Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol 150: 683-691.
11. Cong R, Zhou B, Sun Q, Gu H, Tang N, &, Wang B, (2008): Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 18: 647-656.
12. Congdon N, O'Colmain B, Klaver CCW, et al., (2004): Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol-Chic 122: 477-485.
13. Finger RP, Fimmers R, Holz FG, &, Scholl HP, (2011): Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 52: 4381-4389.
14. Frennesson C, Nilsson UL, Peebo BB, &, Nilsson SEG, (2010): Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmol 88: 420-425.
15. Friedman DS, O'Colmain BJ, Munoz B, et al., (2004): Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572.
16. Geirsdottir A, Jonsson O, Thorisdottir S, Helgadottir G, Jonasson F, Stefansson E, &, Sigurdsson H, (2011): Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load. Br J Ophthalmol [Epub ahead of print].
17. Jonasson F, Gunnlaugsdottir E, &, Arnarsson A, (2010): Five-year incidence of visual impairment and blindness in older Icelanders: the Reykjavik Eye Study. Acta Ophthalmol 88: 358-366.
18. Jonasson F, Arnarsson A, Eiriksdottir G, et al., (2011): Prevalence of age-related macular degeneration in old persons: age, gene/environment susceptibility Reykjavik Study. Ophthalmology 118: 825-830.
19. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, &, de Jong PT, (1998): Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmologica 116: 653-658.
20. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, &, Palta M, (1999): Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 106: 1056-1065.
21. Klein R, Knudtson MD, Lee KE, Gangnon RE, &, Klein BEK, (2008): Age-period-cohort effect on the incidence of age-related macular degeneration-the Beaver Dam Eye Study. Ophthalmology 115: 1460-1467.
22. Klein R, Chou CF, Klein BEK, Zhang XZ, Meuer SM, &, Saaddine JB, (2011): Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol-Chic 129: 75-80.
23. Knudtson MD, Klein R, &, Klein BE, (2006): Physical activity and the 15-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Br J Ophthalmol 90: 1461-1463.
24. Laitinen A, Laatikainen L, Härkänen T, Koskinen S, Reunanen A, &, Aromaa A, (2010): Prevalence of major eye diseases and causes of visual impairment in the adult Finnish population: a nationwide population-based survey. Acta Ophthalmol 88: 463-471.
25. Lotery A, Xu X, Zlatava G, &, Loftus J, (2007): Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 91: 1303-1307.
26. Rein DB, Wittenborn JS, Zhang XZ, Honeycutt AA, Lesesne SB, Saaddine J, & VH Cost-Effectiveness (2009): Forecasting age-related macular degeneration through the year 2050 the potential impact of new treatments. Arch Ophthalmol-Chic 127: 533-540.
27. Seland JH, Vingerling JR, Augood CA, et al., (2011): Visual Impairment and quality of life in the older European population, the EUREYE study. Acta Ophthalmol 89: 608-613.
28. Sjöstrand J, Laatikainen L, Hirvelä H, Popovic Z, &, Jonsson R, (2011): The decline in visual acuity in elderly people with healthy eyes or eyes with early age-related maculopathy in two Scandinavian population samples. Acta Ophthalmol 89: 116-123.
29. Soubrane G, Cruess A, Lotery A, et al., (2007): Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 125: 1249-1254.
30. Taylor HR, Tikellis G, Robman LD, McCarty CA, &, McNeil JJ, (2002): Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 325: 11.
31. Tuulonen A, Salminen H, Linna M, &, Perkola M, (2009): The need and total cost of Finnish eyecare services: a simulation model for 2005-2040. Acta Ophthalmol 87: 820-829.
32. Vinding T, (1989): Age-related macular degeneration-macular changes, prevalence and sex-ratio-an epidemiological-study of 1000 aged individuals. Acta Ophthalmol 67: 609-616.